STAT
The heart possesses limited ability to heal itself.
Following a heart attack or other forms of cardiovascular damage, the heart is unable to regenerate weakened muscle tissue, which impairs its capacity to pump blood effectively throughout the body. Although there have been advancements in medications aimed at alleviating heart failure symptoms — including newer drugs targeting obesity — many patients ultimately confront two primary options: a heart transplant or the implantation of a cardiac device.
Recent findings from a small clinical study indicate promising developments involving an innovative approach. Patients who received patches composed of heart muscle derived from induced pluripotent stem cells experienced an increase in the thickness of their re-muscularized heart walls. This improvement contributed to enhanced pumping functionality and a modest uplift in quality of life. Known as BioVAT, the biological ventricular assist tissue within the patch was designed as a transitional solution, potentially facilitating longer wait times for heart transplants or serving as a precursor to the implantation of a left ventricular assist device (LVAD) in individuals with end-stage heart failure. Future, larger trials will be essential to identify the most suitable candidates for this strategy and to evaluate the long-term effectiveness of the treatment.
Share this story